275 results
8-K
EX-99.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
27 Feb 24
Ligand Reports Fourth Quarter and Full Year 2023 Financial Results
7:24am
valuation allowance during the fourth quarter of 2022, which was partially offset by a non-cash gain of $44.2 million from the value of Ligand's short-
term … , partially offset by an increase in R&D expenses due to the Novan acquisition. General and administrative expenses were $52.8 million for 2023
8-K
EX-10.1
LGND
Ligand Pharmaceuticals, Inc. - Ordinary Shares
17 Oct 23
Entry into a Material Definitive Agreement
7:24pm
Termination Date. Such payment shall be made without any offset, abatement, withholding or reduction whatsoever. Each such payment shall be made
8-K
EX-99.1
vbkwlk py2sw
8 Aug 23
Ligand Reports Second Quarter 2023 Financial Results
4:02pm
8-K
EX-99.1
h4d oo837b
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
8-K
EX-10.1
ic651l i1426luoan
4 Nov 22
Unaudited Pro Forma Condensed Consolidated Financial Statements
4:08pm
425
y5kbpaf
24 Mar 22
Business combination disclosure
9:09am
8-K
EX-2.2
63ioodc7e7 uy6frq
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-2.1
he2 dfq6i5yd9hb
24 Mar 22
Entry into a Material Definitive Agreement
9:08am
8-K
EX-99.1
b2popydg9wrjeqcg
9 Nov 21
Ligand Reports Third Quarter 2021 Financial Results
4:06pm